Suppr超能文献

急性肾衰竭的透析剂量。

Dose of dialysis in acute renal failure.

作者信息

Luyckx Valerie A, Bonventre Joseph V

机构信息

Renal Division, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.

出版信息

Semin Dial. 2004 Jan-Feb;17(1):30-6. doi: 10.1111/j.1525-139x.2004.17111.x.

Abstract

Acute renal failure (ARF) is a cause of significant morbidity and mortality. Despite advances in supportive care, outcomes in ARF have improved little over the past decades. The primary goals in management of patients with ARF are to optimize hemodynamic and volume status, minimize further renal injury, correct metabolic abnormalities, and permit adequate nutrition. Renal replacement therapy (RRT) is often required to achieve these goals while awaiting renal recovery, but the optimal dose of dialysis in patients with ARF is not known. Extrapolation of required dialysis dose from recommendations in chronic dialysis is unlikely to be appropriate because of the lack of a steady state and differences in distribution volume of urea that are intrinsic to ARF. The prescribed dialysis dose in ARF is often low, and actual delivered dose is often even less than prescribed. Delivery of dialysis in ARF is often hampered by the patient's hypercatabolic state, hemodynamic instability, and volume status, as well as suboptimal vascular access with temporary venous catheters. The impact of intermittent hemodialysis (IHD) versus continuous renal replacement therapy (CRRT) on outcomes in ARF is also not clear. Patient disease severity impacts more than dialysis modality in patient outcome, but when patients are stratified for equal disease severity, CRRT may have potential benefits over IHD in terms of patient survival, fluid and metabolic control, and renal recovery. Strategies associated with improved outcomes that have emerged thus far in ARF are to aim for a time-averaged blood urea nitrogen (BUN) of less than 60 mg/dl with IHD, varying IHD frequency as necessary, or to achieve a minimum ultrafiltration rate of 35 ml/kg/hr with CRRT.

摘要

急性肾衰竭(ARF)是导致显著发病和死亡的原因。尽管在支持治疗方面取得了进展,但在过去几十年中,ARF的治疗结果改善甚微。ARF患者管理的主要目标是优化血流动力学和容量状态,尽量减少进一步的肾损伤,纠正代谢异常,并提供充足的营养。在等待肾脏恢复的过程中,通常需要进行肾脏替代治疗(RRT)来实现这些目标,但ARF患者的最佳透析剂量尚不清楚。由于缺乏稳定状态以及ARF固有的尿素分布容积差异,从慢性透析的推荐剂量推断所需的透析剂量不太可能合适。ARF中规定的透析剂量通常较低,而实际输送的剂量往往甚至低于规定剂量。ARF患者的透析输送常常受到患者的高分解代谢状态、血流动力学不稳定和容量状态的阻碍,以及临时静脉导管等血管通路欠佳的影响。间歇性血液透析(IHD)与连续性肾脏替代治疗(CRRT)对ARF治疗结果的影响也不明确。患者疾病严重程度对治疗结果的影响大于透析方式,但当根据疾病严重程度对患者进行分层时,就患者生存、液体和代谢控制以及肾脏恢复而言,CRRT可能比IHD具有潜在优势。迄今为止,在ARF中出现的与改善治疗结果相关的策略是,IHD时目标是使时间平均血尿素氮(BUN)低于60 mg/dl,必要时改变IHD频率,或CRRT时达到至少35 ml/kg/hr的超滤率。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验